Literature DB >> 32851721

Gamma ray-induced glial activation and neuronal loss occur before the delayed onset of brain necrosis.

Baixuan He1, Xia Wang2, Yong He3, Honghong Li1, Yuhua Yang1, Zhongshan Shi1, Qiang Liu1, Minyi Wu1, Haohui Sun1, Jiatian Xie1, Zhan Zhang1, Pei Yu1, Jingru Jiang1, Jinping Cheng1, Jinqing Yang1, Yi Li1, Wei-Jye Lin4,5,6, Yamei Tang1,4,5, Xicheng Wang2.   

Abstract

Radiotherapy is one of the most effective treatments for head and neck tumors. However, delayed radiation-induced brain necrosis (RN) remains a serious issue due to the lack of satisfying prevention and effective treatment. The pathological role of radiation in the delayed onset of brain necrosis is still largely unknown, and the traditional animal model of whole brain irradiation, although being widely used, does not produce reliable and localized brain necrosis mimicking clinical features of RN. In this study, we demonstrated a successful RN mouse model using optimized gamma knife irradiation in male C57BL/6 mice. On the premise that brain necrosis started to appear at 6 weeks postirradiation in our RN model, as confirmed by both MRI and histopathological examinations, we systematically examined different time points before the onset of RN for the histopathological changes and biochemical indicators. Our initial results demonstrated that in the ipsilateral hemisphere of the irradiated brains, a significant decrease in neuronal numbers that occurred at 4 weeks and a sustained increase in TNF-α, iNOS, and other inflammatory cytokines beginning at 1-week postirradiation. Changes of cell morphology and cell numbers of both microglia and astrocytes occurred as early as 1-week postirradiation, and intervention by bevacizumab administration resulted in reduced microglia activation and reduction of radiation-induced lesion volume, indicating that chronic glial activation may result in subsequent elevation of inflammatory factors, which led to the delayed onset of neuronal loss and brain necrosis. Since C57BL/6 is the most widely used strain of genetic engineered mouse model, our data provide an invaluable platform for the mechanistic study of RN pathogenesis, identification of potential imaging and biological biomarkers, and the development of therapeutic treatment for the disease.
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  gamma ray; glial activation; inflammatory cytokine; radiation-induced brain necrosis

Year:  2020        PMID: 32851721     DOI: 10.1096/fj.202000365RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  3 in total

1.  Mortality of early treatment for radiation-induced brain necrosis in head and neck cancer survivors: A multicentre, retrospective, registry-based cohort study.

Authors:  Dong Pan; Xiaoming Rong; Dongping Chen; Jingru Jiang; Wai Tong Ng; Haiqiang Mai; Yi Li; Honghong Li; Jinhua Cai; Jinping Cheng; Yongteng Xu; Melvin Lee Kiang Chua; Charles B Simone; Simona Lattanzi; Yamei Tang
Journal:  EClinicalMedicine       Date:  2022-08-12

2.  Pregabalin mitigates microglial activation and neuronal injury by inhibiting HMGB1 signaling pathway in radiation-induced brain injury.

Authors:  Zhan Zhang; Jingru Jiang; Yong He; Jinhua Cai; Jiatian Xie; Minyi Wu; Mengdan Xing; Zhenzhen Zhang; Haocai Chang; Pei Yu; Siqi Chen; Yuhua Yang; Zhongshan Shi; Qiang Liu; Haohui Sun; Baixuan He; Junbo Zeng; Jialin Huang; Jiongxue Chen; Honghong Li; Yi Li; Wei-Jye Lin; Yamei Tang
Journal:  J Neuroinflammation       Date:  2022-09-21       Impact factor: 9.587

3.  Activation of LRP1 Ameliorates Cerebral Ischemia/Reperfusion Injury and Cognitive Decline by Suppressing Neuroinflammation and Oxidative Stress through TXNIP/NLRP3 Signaling Pathway in Mice.

Authors:  Cheng-Jie Yang; Xin Li; Xiao-Qing Feng; Ye Chen; Jian-Guo Feng; Jing Jia; Ji-Cheng Wei; Jun Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-08-18       Impact factor: 7.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.